

KHP Breast Cancer Biobank Associated Publications 1975-2018

1. Results on a pilot study of cultures of human lacteal secretions and benign and malignant breast tumors. Hallows RC, Millis R, Pigott D, Shearer M, Stoker MG, Taylor-Papadimitriou J. Clin Oncol. 1977 Mar;3(1):81-90.199.
2. Enzyme studies in human breast tumours. Deshpande N, Mitchell I, Millis R. Eur J Cancer. 1977 Nov;13(11):1261-7.
3. Enzymes, lymph node involvement and possible prognosis in human breast cancer. Deshpande N, Mitchell I, Millis R. Eur J Cancer. 1978 Feb;14(2):183-7.
4. Contraceptive steroids and breast cancer. Spencer JD, Millis RR, Hayward JL. Br Med J. 1978 Apr 22;1(6119):1024-6.
5. Glucose metabolism in British and Japanese breast carcinomas. Deshpande N, Mitchell I, Millis R, Kumaoka S. Eur J Cancer. 1978 May;14(5):599-601.
6. Oestrogen receptors and the response to endocrine therapy in advanced breast cancer. Roberts MM, Rubens RD, King RJ, Hawkins RA, Millis RR, Hayward JL, Forrest AP. Br J Cancer. 1978 Sep;38(3):431-6.
7. Elastosis and response to endocrine therapy in human breast cancer. Masters JR, Millis RR, King RJ, Rubens RD. Br J Cancer. 1979 May;39(5):536-9.
8. Primary human breast carcinomas transplantable in the nude mouse. Sebesteny A, Taylor-Papadimitriou J, Ceriani R, Millis R, Schmitt C, Trevan D. J Natl Cancer Inst. 1979 Dec;63(6):1331-7
9. The possibility of accurate prediction of recurrence rates after mastectomy. Bulbrook RD, Wang DY, Millis RR, Hayward JL. Eur J Cancer. 1980;Suppl 1:35-6.
10. Value of needle biopsy in outpatient diagnosis of breast cancer. Fentiman IS, Millis RR, Hayward JL. Arch Surg. 1980 May;115(5):652-3.
11. Assessment of axillary lymph node status. Davies GC, Millis RR, Hayward JL. Ann Surg. 1980 Aug;192(2):148-51.
12. Breast tissue inclusions in axillary lymph nodes. Turner DR, Millis RR. Histopathology. 1980 Nov;4(6):631-6.
13. Correlation of hormone receptors with pathological features in human breast cancer. Millis RR. Cancer. 1980 Dec 15;46(12 Suppl):2869-71
14. Breast cancer in women who have taken contraceptive steroids. Matthews PN, Millis RR, Hayward JL. Br Med J (Clin Res Ed). 1981 Mar 7;282(6266):774-6
15. Tumour enzymes and prognosis in human breast cancer. Deshpande N, Mitchell I, Millis R. Eur J Cancer. 1981 Apr;17(4):443-8.

16. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Stewart JF, King RJ, Sexton SA, Millis RR, Rubens RD, Hayward JL. *Eur J Cancer*. 1981 Apr;17(4):449-53.
17. Pleural effusion in breast cancer: a review of 105 cases. Fentiman IS, Millis R, Sexton S, Hayward JL. *Cancer*. 1981 Apr 15;47(8):2087-92.
18. Histological grade and response to endocrine therapy in breast cancer. Millis RR, Rubens RD, Masters JR, Minton MJ. *Lancet*. 1981 Jul 11;2(8237):101.
19. Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers. Arklie J, Taylor-Papadimitriou J, Bodmer W, Egan M, Millis R. *Int J Cancer*. 1981 Jul 15;28(1):23-9
20. A prospective study of plasma prolactin levels and subsequent risk of breast cancer. Kwa HG, Cleton F, Wang DY, Bulbrook RD, Bulstrode JC, Hayward JL, Millis RR, Cuzick J. *Int J Cancer*. 1981 Dec;28(6):673-6
21. Urinary androgen metabolites and recurrence rates in early breast cancer. Thomas BS, Bulbrook RD, Hayward JL, Millis RR. *Eur J Cancer Clin Oncol*. 1982 May;18(5):447-51
22. The diagnostic value of testing for occult blood. Chaudary MA, Millis RR, Davies GC, Hayward JL. *Ann Surg*. 1982 Dec;196(6):651-5
23. Post-operative serum sialyltransferase levels and prognosis in breast cancer. Stewart J, Rubens R, Millis R, Hayward J, Hoare S, Bulbrook R, Kessel D. *Breast Cancer Res Treat*. 1983;3(2):225-30
24. Thyroid function in early breast cancer. Thomas BS, Bulbrook RD, Russell MJ, Hayward JL, Millis R. *Eur J Cancer Clin Oncol*. 1983 Sep;19(9):1213-
25. Steroid receptors and prognosis in operable (stage I and II) breast cancer. Stewart JF, Rubens RD, Millis RR, King RJ, Hayward JL. *Eur J Cancer Clin Oncol*. 1983 Oct;19(10):1381-7
26. Breast parenchymal patterns in women with bilateral primary breast cancer. Chaudary MA, Gravelle IH, Bulstrode JC, Wang DY, Bulbrook RD, Millis RR, Hayward JL. *Br J Radiol*. 1983 Oct;56(670):703-6
27. Deoxyribonucleic acid (DNA) content of carcinomas and prognosis in human breast cancer. Deshpande N, Mitchell I, Allen D, Millis R. *Int J Cancer*. 1983 Dec 15;32(6):693-6.
28. Needle biopsy of the breast. Millis RR. *Monogr Pathol*. 1984;(25):186-203. Review
29. Serum carcinoembryonic antigen in the diagnosis and prognosis of women with breast cancer. Wang DY, Knyba RE, Bulbrook RD, Millis RR, Hayward JL. *Eur J Cancer Clin Oncol*. 1984 Jan;20(1):25-31.

30. Urinary androgen and 17-hydroxylated corticosteroid metabolites and their relation to recurrence rates in early breast cancer. Thomas BS, Bulbrook RD, Russell MJ, Hayward JL, Millis RR. *Breast Cancer Res Treat.* 1984;4(1):27-35
31. Urinary hydroxyproline and prognosis in human breast cancer. Grant CS, Hoare SA, Millis RR, Hayward JL, Wang DY. *Br J Surg.* 1984 Feb;71(2):105-8
32. Tamoxifen and liver damage. Blackburn AM, Amiel SA, Millis RR, Rubens RD. *Br Med J (Clin Res Ed).* 1984 Aug 4;289(6440):288.
33. Bilateral primary breast cancer: a prospective study of disease incidence. Chaudary MA, Millis RR, Hoskins EO, Halder M, Bulbrook RD, Cuzick J, Hayward JL. *Br J Surg.* 1984 Sep;71(9):711-4
34. Which patients are cured of breast cancer? Fentiman IS, Cuzick J, Millis RR, Hayward JL. *Br Med J (Clin Res Ed).* 1984 Oct 27;289(6452):1108-11
35. Survival following local skin recurrence after mastectomy. Fentiman IS, Matthews PN, Davison OW, Millis RR, Hayward JL. *Br J Surg.* 1985 Jan;72(1):14-6.
36. Family history and bilateral primary breast cancer. Chaudary MA, Millis RR, Bulbrook RD, Hayward JL. *Breast Cancer Res Treat.* 1985;5(2):201-5
37. Deoxyribonucleic acid (DNA) content of primary carcinoma and response to endocrine or cytotoxic drug therapies in patients with advanced breast cancer. Mitchell I, Deshpande N, Millis R, Rubens RD. *Eur J Surg Oncol.* 1985 Sep;11(3):251-6.
38. Patterns of expression of keratin 19 as detected with monoclonal antibodies in human breast tissues and tumours. Bartek J, Taylor-Papadimitriou J, Miller N, Millis R. *Int J Cancer.* 1985 Sep 15;36(3):299-306.
39. Influence of reproductive history on age at diagnosis of breast cancer and prognosis. Wang DY, Rubens RD, Allen DS, Millis RR, Bulbrook RD, Chaudary MA, Hayward JL. *Int J Cancer.* 1985 Oct 15;36(4):427-32
40. Histochemical studies with a monoclonal antibody raised against a partially purified soluble estradiol receptor preparation from human myometrium. King RJ, Coffey AI, Gilbert J, Lewis K, Nash R, Millis R, Raju S, Taylor RW. *Cancer Res.* 1985 Nov;45(11 Pt 2):5728-33.
41. Patterns of reaction of monoclonal antibodies HMFG-1 and -2 with benign breast tissues and breast carcinomas. Taylor-Papadimitriou J, Millis R, Burchell J, Nash R, Pang L, Gilbert J. *J Exp Pathol.* 1986 Summer;2(4):247-60
42. Paget's disease of the nipple: a ten year review including clinical, pathological, and immunohistochemical findings. Chaudary MA, Millis RR, Lane EB, Miller NA. *Breast Cancer Res Treat.* 1986;8(2):139-46
43. Relation between risk of breast cancer and biological availability of estradiol in the blood: prospective study in Guernsey. Bulbrook RD, Moore JW, Clark GM, Wang DY, Millis RR, Hayward JL. *Ann N Y Acad Sci.* 1986;464:378-88.

44. Response to endocrine therapy and breast cancer differentiation. Masters JR, Millis RR, Rubens RD. *Breast Cancer Res Treat.* 1986;7(1):31-4.
45. The activity of phosphohexose isomerase in primary breast carcinomas and response to chemotherapy in patients with metastatic disease. Mitchell I, Deshpande N, Millis R, Rubens RD. *Cancer Chemother Pharmacol.* 1986;17(3):289-91
46. The significance of supraclavicular fossa node recurrence after radical mastectomy. Fentiman IS, Lavelle MA, Caplan D, Miller N, Millis RR, Hayward JL. *Cancer.* 1986 Mar 1;57(5):908-10.
47. Serum prolactin levels in women with breast cancer and their relationship to survival. Wang DY, Hampson S, Kwa HG, Moore JW, Bulbrook RD, Fentiman IS, Hayward JL, King RJ, Millis RR, Rubens RD, et al. *Eur J Cancer Clin Oncol.* 1986 Apr;22(4):487-92.
48. Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Eusebi V, Millis RR, Cattani MG, Bussolati G, Azzopardi JG. *Am J Pathol.* 1986 Jun;123(3):532-41. Erratum in: *Am J Pathol* 1986 Sep;124(3):following 563
49. Effect of the method of biopsy on the prognosis of and reliability of receptor assays in patients with operable breast cancer. Fentiman IS, Millis RR, Chaudary MA, King RJ, Miller KJ, Hayward JL. *Br J Surg.* 1986 Aug;73(8):610-2
50. In situ ductal carcinoma of the breast: implications of disease pattern and treatment. Fentiman IS, Fagg N, Millis RR, Hayward JL. *Eur J Surg Oncol.* 1986 Sep;12(3):261-6.
51. Binding of oestradiol to blood proteins and aetiology of breast cancer. Moore JW, Clark GM, Hoare SA, Millis RR, Hayward JL, Quinlan MK, Wang DY, Bulbrook RD. *Int J Cancer.* 1986 Nov 15;38(5):625-3
52. Acantholytic variant of squamous-cell carcinoma of the breast. Eusebi V, Lamovec J, Cattani MG, Fedeli F, Millis RR. *Am J Surg Pathol.* 1986 Dec;10(12):855-61
53. Histochemical studies with an estrogen receptor-related protein in human breast tumors. Cano A, Coffey AI, Adatia R, Millis RR, Rubens RD, King RJ. *Cancer Res.* 1986 Dec;46(12 Pt 1):6475-80
54. Characterization and biological relevance of a 29-kDa, oestrogen receptor-related protein. King RJ, Finley JR, Coffey AI, Millis RR, Rubens RD. *J Steroid Biochem.* 1987;27(1-3):471-5.
55. Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer. Masters JR, Camplejohn RS, Millis RR, Rubens RD. *Br J Cancer.* 1987 Apr;55(4):455-7
56. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R, Lampert D. *Cancer Res.* 1987 Oct 15;47(20):5476-82

57. Acetylator status and its relationship to breast cancer and other diseases of the breast. Philip PA, Rogers HJ, Millis RR, Rubens RD, Cartwright RA. *Eur J Cancer Clin Oncol*. 1987 Nov;23(11):1701-6.
58. Perioperative bromocriptine adjuvant treatment for operable breast cancer. Fentiman IS, Brame K, Chaudary MA, Camplejohn RS, Wang DY, Millis RR. *Lancet*. 1988 Mar 19;1(8586):609-10
59. Immunohistochemical study of D5 antigen (an oestrogen receptor related protein) in normal breast, benign breast disease, and mammary carcinoma in situ. Girling A, Caleffi M, King RJ, Millis RR. *J Clin Pathol*. 1988 Apr;41(4):448-53.
60. New lumps in the breast following conservation treatment for early breast cancer. Chaudary MM, Girling A, Girling S, Habib F, Millis RR, Hayward JL. *Breast Cancer Res Treat*. 1988 Apr;11(1):51-8
61. Histopathology of benign breast lesions. Millis RR, Girling AC, Fentiman IS. *J Clin Pathol*. 1988 Sep;41(9):1029
62. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS, Altman DG. *Br J Cancer*. 1988 Oct;58(4):448-52
63. Histiocytic lymphoma of breast responds to tamoxifen. Millis RR, Bobrow LG, Rubens RD, Isaacson PG. *Br J Cancer*. 1988 Dec;58(6):808-9.
64. Who needs steroid receptor assays? Barnes DM, Fentiman IS, Millis RR, Rubens RD. *Lancet*. 1989 May 20;1(8647):1126-7.
65. Ductal adenoma of the breast--a review of fifteen cases. Lammie GA, Millis RR. *Hum Pathol*. 1989 Sep;20(9):903-8.
66. An immunohistochemical study of the presence of c-erbB-2 protein in Paget's disease of the nipple. Lammie GA, Barnes DM, Millis RR, Gullick WJ. *Histopathology*. 1989 Nov;15(5):505-14
67. Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. O'Reilly SM, Camplejohn RS, Millis RR, Rubens RD, Richards MA. *Eur J Cancer*. 1990;26(10):1035-8.
68. S100 protein in human mammary tissue--immunoreactivity in breast carcinoma, including Paget's disease of the nipple, and value as a marker of myoepithelial cells. Gillett CE, Bobrow LG, Millis RR. *J Pathol*. 1990 Jan;160(1):19-24
69. Radiation and other pathological changes in breast tissue after conservation treatment for carcinoma. Girling AC, Hanby AM, Millis RR. *J Clin Pathol*. 1990 Feb;43(2):152-6.
70. Diagnostic value of silver-stained interphasic nucleolar organizer regions in breast tumors. Derenzini M, Betts CM, Trerè D, Mambelli V, Millis RR, Eusebi V, Cancellieri A. *Ultrastruct Pathol*. 1990 May-Jun;14(3):233-45.

71. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. O'Reilly SM, Camplejohn RS, Barnes DM, Millis RR, Allen D, Rubens RD, Richards MA. *Br J Cancer*. 1990 May;61(5):671-4.
72. Localization of impalpable breast lesions: a new device. Chaudary MA, Reidy JF, Chaudhuri R, Millis RR, Hayward JL, Fentiman IS. *Br J Surg*. 1990 Oct;77(10):1191-2.
73. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Bartkova J, Barnes DM, Millis RR, Gullick WJ. *Hum Pathol*. 1990 Nov;21(11):1164-7
74. Milk granuloma: an unusual appearance in lactational breast tissue. Rytina ER, Coady AT, Millis RR. *Histopathology*. 1990 Nov;17(5):466-8.
75. Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. O'Reilly SM, Camplejohn RS, Barnes DM, Millis RR, Rubens RD, Richards MA. *J Clin Oncol*. 1990 Dec;8(12):2040-6
76. Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Forrester LM, Hayes JD, Millis R, Barnes D, Harris AL, Schlager JJ, Powis G, Wolf CR. *Carcinogenesis*. 1990 Dec;11(12):2163-70
77. Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Fantl V, Richards MA, Smith R, Lammie GA, Johnstone G, Allen D, Gregory W, Peters G, Dickson C, Barnes DM. *Eur J Cancer*. 1990 Apr;26(4):423-9
78. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, et al. *J Pathol*. 1990 Dec;162(4):285-94
79. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. Barnes DM, Meyer JS, Gonzalez JG, Gullick WJ, Millis RR. *Breast Cancer Res Treat*. 1991 Mar;18(1):11-7
80. Breast cancer in English and Japanese women: prognostic significance of sinus histiocytosis and germinal center hyperplasia in axillary lymph nodes. Friedell GH, Millis RR, Sato T, Suchi T, Shikata I, Chaudary MA, Hayward JL. *Breast Cancer Res Treat*. 1991 May;18 Suppl 1:S73-6
81. Sclerosing lymphocytic lobulitis of the breast--evidence for an autoimmune pathogenesis. Lammie GA, Bobrow LG, Staunton MD, Levison DA, Page G, Millis RR. *Histopathology*. 1991 Jul;19(1):13-20.
82. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA. *Br J Cancer*. 1991 Mar;63(3):444-6
83. Immunohistochemical assessment of tumour behaviour and patient prognosis in human breast cancer. Barnes DM. *Dis Markers*. 1991 May-Aug;9(3-4):159-65.

84. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith PJ, Millis RR. *Eur J Cancer*. 1992;28(2-3):644-8.
85. Mammary hamartoma--a review of 35 cases. Fisher CJ, Hanby AM, Robinson L, Millis RR. *Histopathology*. 1992 Feb;20(2):99-106
86. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, Hayward JL, Millis RR. *Int J Epidemiol*. 1992 Apr;21(2):214-21.
87. Studies of clonal cell lines developed from primary breast cancers indicate that the ability to undergo morphogenesis in vitro is lost early in malignancy. Shearer M, Bartkova J, Bartek J, Berdichevsky F, Barnes D, Millis R, Taylor-Papadimitriou J. *Int J Cancer*. 1992 Jun 19;51(4):602-12.
88. A mucocoele-like tumour of the breast associated with both atypical ductal hyperplasia and mucoid carcinoma. Fisher CJ, Millis RR. *Histopathology*. 1992 Jul;21(1):69-71.
89. Phyllodes tumours: a clinicopathological review of 30 cases. Bennett IC, Khan A, De Freitas R, Chaudary MA, Millis RR. *Aust N Z J Surg*. 1992 Aug;62(8):628-33
90. Flow cytometric characterisation of proliferating cell nuclear antigen using the monoclonal antibody PC10. Wilson GD, Camplejohn RS, Martindale CA, Brock A, Lane DP, Barnes DM. *Eur J Cancer*. 1992;28A(12):2010-7.
91. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in *Escherichia coli*. Midgley CA, Fisher CJ, Bártek J, Vojtěšek B, Lane D, Barnes DM. *J Cell Sci*. 1992 Jan;101 (Pt 1):183-9.
92. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Barnes DM, Hanby AM, Gillett CE, Mohammed S, Hodgson S, Bobrow LG, Leigh IM, Purkis T, MacGeoch C, Spurr NK, et al. *Lancet*. 1992 Aug 1;340(8814):259-63
93. KiS1--a novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma. Sampson SA, Kreipe H, Gillett CE, Smith P, Chaudary MA, Khan A, Wicks K, Parwaresch R, Barnes DM. *J Pathol*. 1992 Oct;168(2):179-85. Erratum in: *J Pathol* 1993 Feb;169(2):287
94. Expression of the ERBB3 gene product in breast cancer. Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC. *Br J Cancer*. 1992 Dec;66(6):1116-21
95. Patterns of metastatic breast cancer in relation to histological type. Jain S, Fisher C, Smith P, Millis RR, Rubens RD. *Eur J Cancer*. 1993;29A(15):2155-7

96. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Bartkova J, Bartek J, Vojtesek B, Lukas J, Rejthar A, Kovarik J, Millis RR, Lane DP, Barnes DM. *Eur J Cancer*. 1993;29A(6):881-6
97. Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. Rasbridge SA, Gillett CE, Sampson SA, Walsh FS, Millis RR. *J Pathol*. 1993 Feb;169(2):245-50.
98. Microglandular adenosis, apocrine adenosis, and tubular carcinoma of the breast. An immunohistochemical comparison. Eusebi V, Foschini MP, Betts CM, Gherardi G, Millis RR, Bussolati G, Azzopardi JG. *Am J Surg Pathol*. 1993 Feb;17(2):99-109
99. Breast lymphomas: a clinicopathologic review. Bobrow LG, Richards MA, Happerfield LC, Diss TC, Isaacson PG, Lammie GA, Millis RR. *Hum Pathol*. 1993 Mar;24(3):274-8. Review
100. Oestrogen and progesterone receptor expression in mammary fibromatosis. Rasbridge SA, Gillett CE, Millis RR. *J Clin Pathol*. 1993 Apr;46(4):349-51
101. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. *Hum Pathol*. 1993 May;24(5):469-76
102. Age as prognostic factor in premenopausal breast cancer. Richards MA, Gregory WM, Smith P, Millis RR, Fentiman IS, Rubens RD. *Lancet*. 1993 Jun 5;341(8858):1484-5
103. Ki-S1, a novel proliferative marker: flow cytometric assessment of staining in human breast carcinoma cells. Camplejohn RS, Brock A, Barnes DM, Gillett C, Raikundalia B, Kreipe H, Parwaresch MR. *Br J Cancer*. 1993 Apr;67(4):657-62
104. TGF alpha and TGF beta expression in mammary carcinoma. Dublin EA, Barnes DM, Wang DY, King RJ, Levison DA. *J Pathol*. 1993 May;170(1):15-22.
105. Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Vojtěšek B, Fisher CJ, Barnes DM, Lane DP. *Br J Cancer*. 1993 Jun;67(6):1254-8
106. Comparison of three cell cycle associated antigens as markers of proliferative activity and prognosis in breast carcinoma. Gillett CE, Barnes DM, Camplejohn RS. *J Clin Pathol*. 1993 Dec;46(12):1126-8.
107. p53 protein detected by immunohistochemical staining is not always mutant. MacGeoch C, Barnes DM, Newton JA, Mohammed S, Hodgson SV, Ng M, Bishop DT, Spurr NK. *Dis Markers*. 1993 Dec;11(5-6):239-50
108. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Fisher CJ, Gillett CE, Vojtěšek B, Barnes DM, Millis RR. *Br J Cancer*. 1994 Jan;69(1):26-31.

109. Benign lymph node inclusions mimicking metastatic carcinoma. Fisher CJ, Hill S, Millis RR. *J Clin Pathol.* 1994 Mar;47(3):245-7
110. The classification of ductal carcinoma in situ and its association with biological markers. Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis RR. *Semin Diagn Pathol.* 1994 Aug;11(3):199-207
111. Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component. Lampejo OT, Barnes DM, Smith P, Millis RR. *Semin Diagn Pathol.* 1994 Aug;11(3):215-22
112. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Rasbridge SA, Gillett CE, Seymour AM, Patel K, Richards MA, Rubens RD, Millis RR. *Br J Cancer.* 1994 Aug;70(2):335-41
113. Primary lymphoma of the breast and lymphocytic lobulitis. Lee AH, Millis RR, Bobrow LG. *Histopathology.* 1994 Sep;25(3):297-8
114. The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre. Camplejohn RS, Ash CM, Gillett CE, Raikundalia B, Barnes DM, Gregory WM, Richards MA, Millis RR. *Br J Cancer.* 1995 Jan;71(1):140-5.
115. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. Bobrow LG, Happerfield LC, Gregory WM, Millis RR. *J Pathol.* 1995 Aug;176(4):333-41
116. Carcinoma in situ involving sclerosing adenosis: a mimic of invasive breast carcinoma. Rasbridge SA, Millis RR. *Histopathology.* 1995 Sep;27(3):269-73
117. Cyclical tumour variations in premenopausal women with early breast cancer. Badwe RA, Bettelheim R, Millis RR, Gregory W, Richards MA, Fentiman IS. *Eur J Cancer.* 1995 Dec;31A(13-14):2181-4.
118. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Labrecque LG, Barnes DM, Fentiman IS, Griffin BE. *Cancer Res.* 1995 Jan 1;55(1):39-45.
119. Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical staining. MacGeoch C, Turner G, Bobrow LG, Barnes DM, Bishop DT, Spurr NK. *J Med Genet.* 1995 Mar;32(3):186-90.
120. Loss of heterozygosity of the oestrogen receptor gene in breast cancer. Iwase H, Greenman JM, Barnes DM, Bobrow L, Hodgson S, Mathew CG. *Br J Cancer.* 1995 Mar;71(3):448-50
121. Lymphocytic Lobulitis and Carcinoma of the Breast. AHS Lee, LG Bobrow and RR Millis. (Letter) *Histopathology.* 1996, **28**:94-95

122. Tissue Plasminogen Activator production by monocytes in venous thrombosis. K Soo, ADR Northeast, LC Happerfield, KG Burnand and LG Bobrow. *J Pathol.* 1996, **178**:190-194.
123. IL2 therapy is a model of inflammation. DW Miles, LC Happerfield, LG Bobrow and RD Rubens. *Histopathology* 1996, **28**: 301-308
124. Cyclin D1 and prognosis in human breast cancer. CE Gillett, P Smith, WM Gregory, MA Richards, RR Millis, G Peters and DM Barnes. *Int J Cancer* 1996, **69**:92-99.
125. Expression of Adhesion Molecules on the microvasculature of the Pharyngeal Tonsil (Adenoid). ME Perry, NA Kirkpatrick, LC Happerfield and MJ Gleeson. *Acta Otol (suppl)*. 1996, **523**:47-51.
126. Immunohistochemical evaluation of biological markers in mammar carcinoma in situ: correlation with morphological features and recently proposed schemes for histological classification. RR Millis, LG Bobrow and DM Barnes. *Breast* 1996, **5**:113-122
127. Comparison of immunohistological staining with different antibodies to c-erbB2 oncoprotein. LG Bobrow, LC Happerfield and RR Millis. *Applied Immunohistochemistry*, 1996, **4**: 128-134
128. p53, apoptosis and breast cancer. DM Barnes and RS Camplejohn. *J. Mam Gland Biol Neo*, 1996. **1**:163-175
129. p53-MDM2 interaction, a novel therapeutic target. Picksley SM, Spicer JF, Barnes DM and Lane DP. *Acta Oncologica*, 1996. **35**:429-434.
130. Inflammatory infiltrate in invasive lobular and ductal carcinoma of the breast AHS Lee, LC Happerfield, RR Millis and LG Bobrow *Br J Cancer*, 1996. **74**: 796-801.
131. Immunohistochemical determination of oestrogen receptor - Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer. DM Barnes, WH Harris, P Smith, RR Millis and RD Rubens. *Br J Cancer*, 1996 **74**: 1445-1451
132. Combined loss of brca1/ brca2 in grade 3 breast carcinomas. DP Kelsall, NK Spurr, DM Barnes and DP Lane. *Lancet* 1996 **347**:1554-1555.
133. Assessment of oestrogen and progesterone receptor antibodies in formalin-fixed routinely processed paraffin-wax embedded tissue. LC Happerfield, G Echezarreta, CE Gillett, AM Hanby, DM Barnes, LG Bobrow. *J. Cellular Pathology*, 1996 **1**: 170-178
134. The p53-mdm2 interaction in a cancer prone family and the identification of a novel therapeutic target. *Acta Oncologica*, 1996 **35**: 429-434.
135. A comparative immunohistochemical study of mammary Paget's disease and superficial spreading melanoma with particular emphasis on melanocytic markers. S Ramachandra, CE Gillett and RR Millis. *Virchows Arch* 1996 **429**: 371-376.

136. One view and 2 view mammography in breast cancer - Are carcinomas detected by one and 2 view mammography similar? AHS Lee, LG Bobrow and RR Millis *BMJ*, 1996 **312**: 508-509.
137. Sequence variants of the oestrogen receptor (er) gene found in breast cancer patients with er negative and progesterone receptor positive tumors. H Iwase, JM Greenman, DM Barnes, S Hodgson, L Bobrow and CG Mathew. *Cancer Letters*, 1996 **108**: 179-184.
138. Sclerosing lymphocytic lobulitis in the male breast. AHS Lee, B Zafrani, G Kafiri, S Rozan and RR Millis. *J Clin Pathol*, 1996 **49**: 609-611.
139. Angiogenesis and inflammation in Ductal Carcinoma in situ of the breast. AHS Lee, LC Happerfield, LG Bobrow and RR Millis. *J. Pathol*, 1997 **181**: 200-206.
140. Cyclin D1 in mammary carcinoma (Editorial). DM Barnes. *J Pathol*, 1997 **181**: 267-269.
141. Body weight and vascular invasion in postmenopausal women with breast cancer. RA Badwe, IS Fentiman, RR Millis and WM Gregory. *Br J. Cancer*, 1997 **75**: 910-913.
142. Histopathology of breast cancer in relation to age. CJ Fisher, MK Egan, P Smith, K Wicks, RR Millis, IS Fentiman. *Br J.Cancer*, 1997 **75**: 593-596.
143. Mucoid breast carcinomas: histology and prognosis. IS Fentiman, RR Millis, P Smith, JPM Ellul, O Lampejo. *Br J. Cancer*, 1997 **75**: 1061-1065.
144. Breast cancer- From clinic to laboratory. CE Gillett and LC Happerfield. *Br J Biomed Sci*, 1997 **54**: 47-56.
145. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family. ME Lomax, DM Barnes, R Gilchrist, SM Picksley, JM Varley and RS Camplejohn. *Oncogene*, 1997 **14**: 1869-1874.
146. High level expression of p27^{kip1} and cyclin D1 in some proliferating cells: inverse correlation with the degree of malignancy in human breast and colorectal cancers. S Fredersdorf, J Burns, AM Milne, G Packham, L Fallis, CE Gillett, JA Royds, D Peston, PA Hall, AM Hanby, DM Barnes, S Shoushe, MJ O'Hare and X Lu. *PNAS*, 1997 **94**: 6380-6385.
147. Allele loss, replication errors and loss of expression of e-cadherin in colorectal cancers. M Ilyas, IPM Tomlinson, A Hanby, IC Talbot and WF Bodmer. *Gut*, 1997 **40**: 654-659.
148. The molecular pathology of neoplasia, overview. AM Hanby *Cancer and Metastasis Reviews*, 1997 **16**: 1-3.
149. T cell receptor $\alpha\beta$ -deficient mice fail to develop colitis in the absence of a microbial environment. L Dianda, A Hanby, Sebesteny, A Hayday and MJ Owen. *Am J Pathol*, 1997 **1**: 91-97.

150. Comparison of four endothelial antibodies for assessing angiogenesis of the breast. AHS Lee, LG Bobrow and LC Happerfield. *J Cell Pathol*, 1997 **2**: 67-73.
151. The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. JC Keen, JM Dixon, EP Miller, DA Cameron, U Chetty, A Hanby, C Bellamy, WR Miller. *Breast Cancer Res Treat*, 1997 **44**: 123-133.
152. Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer. P Steiner, DM Barnes, WH Harris and RA Weinberg. *Nature Genetics*, 1997 **16**: 332-333.
153. Intestinal trefoil factor hPI.B and pS2 but not spasmodic polypeptide mRNAs are co-expressed in hyperplastic and neoplastic human breast epithelium. R Poulsom, AM Hanby, E-N Lalani, F Hauser, W Hoffman and G Stamp. *J Pathol*, 1997 **183**: 30-38
154. Primary metaplastic carcinoma (carcinosarcoma) of the skin - a small clinicopathological series and review of the literature. NK Patel, PH McKee, NP Smith and CDM Fletcher. *Am J Dermatopathol*, 1997 **19**: 363-372.
155. Apocrine differentiation in breast epithelium. V Eusebi, S Damiani, L Losi and RR Millis. *Advances in Anatomic Pathology*, 1997 **4**: 139-155.
156. Angiogenesis and inflammation in invasive carcinoma of the breast. AHS Lee , LC Happerfield, LG Bobrow, RR Millis. *J Clin Pathol*, 1997 **50**: 669-673.
157. The localisation of the Insulin-like growth factor receptor 1 (IGFR 1) in benign and malignant breast tissue. LC Happerfield, DW Miles, LL Thomsen, DM Barnes and AM Hanby. *J Pathol*, 1997 **183**: 412-417.
158. Loco-regional recurrence following mastectomy for early breast carcinoma efficiency of radiotherapy at the time of recurrence. Chaudary MA, Tong D, Millis R, Smith P, Fentiman IS, Rubens RD *Eur J Surg Onc*, 1997 **23**: 348-353.
159. Duodenal content reflux oesophagitis in the rat: an animal model for the ulcer associated cell-lineage (UACL)? AM Hanby, M Pera, I Filipe, R Poulsom, NA Wright, M Pera, L Grande and A Duranceau *Am J Pathol*, 1997 **151**: 1819-1824.
160. CerbB3 protein expression in ductal carcinoma in-situ of the breast. LG Bobrow, RR Millis, LC Happerfield and WJ Gullick. *Eur J Cancer*, 1997 **33**: 1846-1850.
161. p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer. EA Dublin, DW Miles, RD Rubens, P Smith and DM Barnes. *Int J Cancer*, 1997 **74**: 605-608.
162. Amplification and over-expression of the *MDM2* gene in human soft tissue tumours. H Patterson, DM Barnes, S Gill, J Spicer, C Fisher, M Thomas, R Grimer, C Fletcher, B Gusterson and C Cooper. *Sarcoma* 1, 1997 **1**: 17-22.

163. Consensus conference on the classification of ductal carcinoma in situ. GF Schwartz, MD Lagios, D Carter, J Connolly, IO Ellis, V Eusebi, GC Finkel, F Gorstein, R Holland, ...RR Millis, et al. *Cancer*, 1997 **80**: 1798-1802.
164. p53 protein expression in human breast cancer: Relationship to tumour differentiation and endocrine response. RI Nicholson, JMW Gee, LT Seery, RA McClelland, ME Harper, B Holt, D Barnes, JFR Robertson, S Pinder and IO Ellis. *Scientific Updates 1*, Elsevier Science B.V. ed JGN Klijn, 1997 95-114.
165. Comparative-analysis of integrins in vivo and in vitro in uveal and cutaneous melanomas. JF Marshall, DC Rutherford, LC Happerfield, ACE McCartney, JN Newton-Bishop, AM Hanby and I Hart. *Br J Cancer*, 1998 **77**: 522-529
166. A microsatellite within the MUC1 locus on 1q21 is altered in the neoplastic cells of breast cancer patients. MR Waltz, SM Pandelidis, W Pratt, DM Barnes, DM Swallow, SJ Gendler and EP Cohen. *Cancer Genet Cytogenet*, 1998 **100**: 63-67
167. Expression of estrogen-receptor and estrogen-inducible genes ps2 and erd5 in large-bowel mucosa and cancer. S Singh, R Poulson, AM Hanby, LA Rogers, NA Wright, MC Sheppard and MJS Langman. *J Pathol*, 1998 **184**: 153-160
168. Retinoblastoma and p16 proteins in mammary carcinoma: Their relationship to cyclin D1 and histopathological parameters. EA Dublin, NK Patel, CE Gillett, P.Smith, G.Peters and DM Barnes. *Int J Cancer (Pred Oncol)*, 1998 **79**: 71-75
169. Adenomyoepithelioma of the breast with malignant features. SA Rasbridge and RR Millis. *Virchows Archiv*, 1998 **432**: 123-130
170. Stromelysin 3: An independent prognostic factor for relapse-free survival in node positive breast cancer and demonstration of novel breast carcinoma cell expression. A Ahmad, AM Hanby, EA Dublin, P Smith, DM Barnes, P Basset, JP Bellocq and IR Hart. *Am J Pathol*, 1998 **152**: 721-728
171. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. CE Gillett, AHS Lee, RR Millis and DM Barnes. *J.Pathol*, 1998 **184**: 396-400
172. Identification of missense and truncating mutations in the BRCA1 gene in sporadic and familial breast and ovarian cancer. J Greenman, S Mohammed, D Ellis, S Watts, G Scott, L Izatt, D Barnes, E Solomon, S Hodgson and C Matthew. *Gene Chromosomes Cancer*, 1998 **21**: 244-249
173. Cell proliferation measured by MIB1 and timing of surgery for breast cancer. LS Cooper, CE Gillett, P Smith, I Fentiman, DM Barnes. *Br J Cancer*, 1998 **77**: 1502-1507
174. Family history and survival in pre-menopausal breast cancer. S Mohammed, P Smith, S Hodgson, IS Fentiman, DM Barnes, RR Millis and RD Rubens. *Br J Cancer*, 1998 **77**: 2252-2256

175. Tumor grade does not change between primary and recurrent mammary carcinoma. RR Millis, DM Barnes, OT Lampejo, MK Egan, P Smith. Eur J Cancer, 1998 **34**: 548-553
176. Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. AHS Lee, EA Dublin and LG Bobrow. J Pathol, 1998 **185**: 394-401
177. Fortuitous diagnosis in a uterine leiomyoma of metastatic lobular carcinoma of the breast. RD Liebmann, KD Jones, R Hamid, M Lapsley. Histopath (letter), 1998 **32**: 577-578
178. Immunohistochemical expression of BRCA2 protein and allelic loss at the *BRCA2* locus in prostate cancer. SM Edwards, WD Dunsmuir, CE Gillett, SR Lakhani, C Corbishley, M Young, RS Kirby, DP Dearnaley, A Dowe, A Ardern-Jones, DM Barnes and RA Eeles. Int J Cancer, 1998 **78**: 1-7
179. Primary mucinous carcinoma of the skin express TFF1, TFF3, estrogen receptor and progesterone receptor. AM Hanby, P McKee, M Jeffrey, W Grayson, EA Dublin, R Poulosom and B McGuire. Am J Surg Pathol, 1998 **22**: 1125-1131
180. Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: A comparative study with long follow-up. S Badve, R A'Hern, A Ward, RR Millis, SE Pinder, IO Ellis, BA Gusterson and JP Sloane. Human Pathol 1998 **29**: 915-923
181. Characterisation of p53 oligomerisation domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. ME Lomax, DM Barnes, TR Hupp, SM Picksley and RS Camplejohn. Oncogene 1998 **17**: 643-649
182. Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. DM Barnes, RR Millis, LVAM Beex, SM Thorpe and RE Leake. Eur J cancer 1998 **34**: 1677-1682
183. p53 immunoreactivity does not deteriorate in stored paraffin sections. LS Cooper, CE Gillett, AM Hanby and DM Barnes. Breast 1998 **7**: 260-264
184. Interstitial laser photocoagulation of normal lung parenchyma in rats. DI Fielding, G Buonaccorsi, A Hanby, MR Hetzel and SG Brown. Thorax 1998 **53**: 692-697
185. Cell Cycle Demystified. DM Barnes and CE Gillett. J Clin Pathol: Mol Pathol 1998 **51**: 310-316
186. Cyclin D1 in breast cancer. DM Barnes and CE Gillett. Breast Cancer Res Treat 1998 **52**: 1-15
187. Proliferation markers in histopathology. CE Gillett and DM Barnes. In Crocker J and Burnett D (eds) The Science of Laboratory Diagnosis, Isis Medical Media Ltd, Oxford pp 86-100

188. Cyclin dependent kinase inhibitor p27^{Kip1} expression and interaction with other cell cycle associated proteins in mammary carcinoma. CE Gillett, P Smith, G Peters, X Lu and DM Barnes. *J Pathol* 1999 **187**: 200-206
189. Differential expression of keratins 10, 17 and 19 in normal cervical epithelium, cervical intraepithelial neoplasia and cervical carcinoma. P Maddox, P Sasieni, A Szerewski, M Anderson and A Hanby. *J Clin Pathol* 1999 **52**: 41-46
190. Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma *in situ* of the breast. AHS Lee, EA Dublin and LG Bobrow. *J Pathol* 1999 **187**: 285-290
191. The mucous neck cell in the human gastric corpus: A distinctive, functional cell lineage. AM Hanby, R Poulsom, RJ Playford and NA Wright. *J Pathol* 1999 **187**: 331-337
192. Expression and function of BRCA1 and BRCA2 in familial and sporadic breast cancer. D M Barnes. *Histopathology* 1999 **34**: 170-174
193. Time related effects of oestrogen withdrawal on proliferation- and cell death related events in MCF7 xenografts. S Detre, J Slater, DM Barnes, S Riddler, M Hills, SRD Johnston, C Gillett, R A'Herne and M Dowsett. *Int J Cancer* 1999 **81**: 309-313
194. Comparative genomic hybridisation of breast tumours stratified by histological grade reveals new insights into the biological progression of breast cancer. R Roylance, P Gorman, W Harris, R Liebmann, D Barnes, A Hanby and D Sheer. *Cancer Research* 1999 **59**: 1433-1436
195. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. SJ Houston, TA Plunkett, DM Barnes, P Smith, RD Rubens and DW Miles. *Br J Cancer* 1999 **79**: 1220-1226
196. Imaging protein kinase C α activation in cells. T Ng, A Squire, G Hansra, F Bornancin, C Prevostel, A Hanby, W Harris, D Barnes, S Schmidt, H Mellor, PIH Bastiaens and PJ Parker. *Science* 1999 **283**: 2085-2089
197. Methylation of the BRCA 1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics. A Catteau, WH Harris, CF Xu and E Solomon. *Oncogene* 1999 **18**: 1957-1965
198. The Breast. RR Millis, AM Hanby, HA Oberman. In *Diagnostic Surgical Pathology*, third edition, (ed) S. Sternberg. Lippincott Williams & Wilkins, Philadelphia 1999 pp 319-385
199. p21^{WAF1} expression and endocrine response in breast cancer. RA McClelland, JMW Gee, L O'Sullivan, DM Barnes, JFR Robertson, IO Ellis and RI Nicholson. *J Pathol* 1999 **188**: 126-132
200. Fine needle interstitial photodynamic therapy of the lung parenchyma - Photosensitizer distribution and morphologic effects of treatment. DI Fielding, GA

- Buonaccorsi, AJ MacRobert, AM Hanby, MR Hetzel and SG Brown. *Chest* 1999 **115**: 502-510
201. A novel gene (*PLU-1*) containing highly conserved putative DNA/ Chromatin binding motifs is specifically up-regulated in breast cancer. PJ Lu, K Sundquist, D Baeckstrom, R Poulson, A Hanby, S Meier-Ewert, T Jones, M Mitchell, P Pitha-Rowe, P Freemont and J Taylor-Papadimitriou. *J Biol Chem*, 1999 **274**: 15633-15645
 202. The expression of c-erbB2 and p53 protein is similar in breast cancer from British and Japanese women. WJ Merchant, RR Millis, P Smith, MA Chaudary and DM Barnes. *Int J Cancer*, 1999 **84**: 278-283
 203. Minimal breast cancer: Evaluation of histology and biological marker expression. EA Dublin, RR Millis, P Smith and LG Bobrow. *Br J Cancer*, 1999 **80**: 1608-1616
 204. HLA Class II DRB1 and DQB1 allelic polymorphism and sclerosing lymphocytic lobulitis of the breast. AHS Lee, AC Bateman, SJ Turner, JM Theaker and WM Howell. *J. Clin Pathol*, 1999 **52**: 445-449
 205. X-ray scatter signatures for normal and neoplastic breast tissues. G Kidane, RD Speller, GJ Royle and AM Hanby. *Phys Med Biol* 1999 **44**: 1791-1802
 206. Effect of c-erbB2 and oestrogen receptor status on survival of women with breast cancer treated with adjuvant Cyclophosphamide/Methotrexate/Fluoracil. DW Miles, WH Harris, CE Gillett, P Smith and DM Barnes. *Int J Cancer*, 1999 **84**: 354-359
 207. The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast. DSP Tan, HWW Potts, ACK Leong, CE Gillett, D Skilton, WH Harris, RD Liebmann and AM Hanby. *J Pathol* 1999 **189**:20-27
 208. Predictive factors in response to systemic treatment. DM Barnes and CE Gillett *Current Medical Literature (Invited Comment)* 1999 **11**: 57-64
 209. Identification by differential display of a protein phosphatase - 2A regulatory subunit preferentially expressed in malignant melanoma cells. G Francia, R Poulson, AM Hanby, SD Mitchell, G Williams, P McKee and IR Hart. *Int J Cancer* 1999 **82**: 709-713
 210. Survival of premenopausal breast carcinoma patients in relation to menstrual cycle timing of surgery and estrogen receptor/ progesterone receptor of the primary tumour. LS Cooper, CE Gillett, NK Patel, DM Barnes and IS Fentiman. *Cancer* 1999 **86**: 2053-2058
 211. Identification of germline missense mutations and rare allelic variants in the *ATM* gene in early-onset breast cancer. L Izatt, J Greenman, S Hodgson, D Ellis, S Watts, G Scott, C Jacobs, R Liebmann, MJ Zvelebil, C Matthew and E Solomon. *Gene Chromosome Cancer* 1999 **26**: 286-294
 212. The role of the subspecialized histopathologist in the treatment of invasive breast cancer: Determination of distinct biologies of clinical relevance. AM Hanby. *Current Medical Literature (Invited Comment)*, 1999 **11**: 85-90

213. An α 2,3 sialyltransferase (ST3 Gal I) is elevated in primary breast carcinomas. J Burchell, R Poulson, A Hanby, C Whitehouse, L Cooper, H Clausen, D Miles and J Taylor-Papadimitriou. *Glycobiology* 1999 **9**:1307-1311
214. Response of metastatic breast cancer to trastuzumab. Commentary. DM Barnes and DW Miles. *Lancet*, 2000 **355**: 206-207
215. Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast. ACK Leong, AM Hanby, HWW Potts, DSP Tan, D Skilton, K Ryder, WH Harris, RD Liebmann, DM Barnes and CE Gillett. *Int J Cancer*, 2000 **89**: 26-31
216. The reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: inter-laboratory variance in the sensitivity of detection and evaluation of scoring systems. A Rhodes, B Jasani, DM Barnes, LG Bobrow and KD Miller. *J Clin Pathol*, 2000 **53**: 125-130
217. The value of rapid functional assays of germline p53 status in LFS and LFL families. RS Camplejohn, N Sodha, R Gilchrist, ME Lomax, PM Duddy, C Miner, P Alarcon-Gonzalez, DM Barnes, RA Eeles. *Br J Cancer*, 2000 **82**: 1145-1148
218. Molecular analysis of phyllodes tumours reveals distinct changes in the epithelial and stromal components. E Sawyer, A M Hanby, S Lakhani, I Ellis, S Boyle, P Ellis, I Tomlinson. *Am J Pathol*, 2000 **156**: 1093-1098
219. A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. CQ.Lin, K.Murata, J.Singh, Y.Itahana, SH.Liang, CE.Gillett, J.Campisi, and PY.Desprez. *Cancer Res*, 2000 **60**: 1332-1340
220. Nuclear expression of the c-erbB4 growth factor receptor in invasive breast cancers. R. Srinivasan, CE Gillett, DM Barnes and WJ Gullick. *Cancer Res* 2000 **60**: 1483-1487
221. APC mutations are sufficient for the growth of early colorectal adenomas. H Lamlum, A Papadopoulou, M Ilyas, A Rowan, C Gillett, A Hanby, I Talbot, W Bodmer, I Tomlinson. *PNAS*, 2000 **97**: 2225-2228
222. Effective tamoxifen therapy of breast cancer involves both antiproliferative and proapoptotic changes. DA Cameron, JC Keen, JM Dixon, C Bellamy, A Hanby, TJ Anderson, WR Miller. *Eur J Pathol*, 2000 **36**: 845-851
223. The androgen receptor exon 1 trinucleotide repeat does not act as a modifier of the age of presentation in breast cancer. HF Given, R Radbourne, H Oag, S Merritt, E Barclay, AM Hanby, H Lamlum, J McGrath, C Curran and IPM Tomlinson. *Eur J Cancer* 2000 **36**: 533-534.
224. Immunohistochemical detection of steroid receptors in breast cancer: A working protocol. R Leake, D Barnes, S Pinder, I Ellis, L Anderson, T Anderson, R Adamson, T Rhodes, K Miller and R Walker on behalf of the UK Receptor Group, UK NEQAS, the Scottish Breast Cancer Pathology Group and the Receptor and Biomarker Study Group of the EORTC. *J Clin Pathol*, 2000 **53**: 634-635.

225. Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay. PM Duddy, AM Hanby, DM Barnes, RS Camplejohn. *J Mol Diag* 2000 **2**: 139-144.
226. The frequency of germ-line mutations in the breast cancer predisposition genes, *BRCA1* and *BRCA2* in familial prostate cancer. SA Gayther, KAF de Foy, P Harrington, P Pharoah, WD Dunsmuir, SM Edwards, C Gillett, A Ardern-Jones, DP Dearnaley, DF Easton, D Ford, RJ Shearer, RS Kirby, AL Dowe, J Kelly, MR Stratton, The CRC/ British Prostate Group UK Familial Prostate Cancer Study Collaborators, BAJ Ponder, D Barnes and RA Eeles. *Cancer Research*, 2000 **60**: 4513-4518
227. Association between LOH of *BRCA1* and *BRCA2* and morphological attributes of sporadic breast cancer AM Hanby, DP Kelsell, HWW Potts, CE Gillett, DT Bishop, NK Spurr and DM Barnes *Int J Cancer*, 2000 **88**: 204-208
228. *In situ* analysis of LKB1/STK11 mRNA expression in human normal tissues and tumours. A Rowan, M Churchman, R Jeffrey, A Hanby, R Poulson and I Tomlinson. *J Pathol*, 2000 **192**: 203-206
229. Immunohistochemical expression of uPA, uPAR and PAI-1 in breast carcinoma: Fibroblastic expression has strong associations with tumour pathology and patient outcome. EA Dublin, AM Hanby, NK Patel, RD Liebman and DM Barnes. *Am J Pathol*, 2000 **157**: 1219-1227
230. Expression of E-cadherin, cellular differentiation and polarity in epithelial salivary neoplasms. P Economopoulou, A Hanby and EW Odell. *Eur J Oncology (oral oncology)* 2000 **36**: 515-518
231. Molecular Markers for predicting prostate cancer stage and survival. WD Dunsmuir, CE Gillett, LC Meyer, MP Young, C Corbishley, RA Eeles and RS Kirby. *Br J Urol Int* 2000 **86**: 869-878
232. Multiple tissue core arrays in histopathology research: a validation study. CE Gillett, RJ Springall, DM Barnes, AM Hanby. *J Pathol* 2000 **192**: 549-553
233. A study of the value of p53, HER2 and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. A Hamilton, D Larismont, R Paridaens, M Drijkoningen, M van de Vijver, P Bruning, A Hanby, S Houston, I Treilleux, J-P Guastalla, A. van Vreckem, R Sylvester and M Piccart. *Clin Breast Cancer* 2000 **1**: 233-240
234. Expression of CD34 and bcl-2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast. T Moore and AHS Lee. *Histopathology* 2001 **38**: 62-67
235. Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. A-M Cleton-Jansen, DF Callen, R Seshardi, S Goldup, B McCallum, J Crawford, JA. Powell, C Settasatian, H van Beerendonk, EW. Moerland, VTBHM Smit, WH. Harris, R Millis, NV Morgan, D Barnes, CG Mathew, CJ. Cornelisse. *Cancer Research*, 2001 **61**: 1171-1177

236. Retention of the expression of E-cadherin and catenins correlates with poor outcome in grade III ductal carcinoma of the breast. CE Gillett, DW Miles, K Ryder, D Skilton, RD Liebman, RJ Springall, DM Barnes and AM Hanby. *J Pathol*, 2001 **193**: 433-441
237. Oestrogen and Progesterone Receptors: Past, Present and Future (Commentary). DM Barnes, AM Hanby. *Histopathology*, 2001, **38**: 271-274
238. Study of interlaboratory reliability and reproducibility of oestrogen and progesterone receptor assays in Europe - Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. A Rhodes, B Jasani, AJ Balaton, DM Barnes, E Anderson, LG Bobrow, KD Miller. *Am J Clin Pathol* 2001 **115**: 44-58
239. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. S Droufakou, V Deshmane, R Roylance, A Hanby, I Tomlinson, IR Hart. *Int J Cancer* 2001 **92**: 404-408
240. Assessment of cellular proliferation by calculation of mitotic index and by immunohistochemistry. CE Gillett, 2001 pp123-131. In *Methods in Molecular Medicine*, vol 57: *Metastasis Research protocols*, vol 1: Analysis of cells and tissues. Ed SA Brooks and U Schumacher. Humana Press Inc, Totowa, NJ
241. Expression of the microtubule binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells. V Assman, CE Gillett, K Ryder, R Poulson, IR Hart, AM Hanby. *J Pathol*, 2001 **195**: 191-196
242. Allelic imbalance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways. R Roylance, P Gorman, A Hanby, I Tomlinson. *J Pathol* 2002 196: 32-36
243. Maximising the role of mitotic count can improve prognosis of grade II infiltrating ductal carcinoma. J Lynch, R Pattekar, DM Barnes, AM Hanby, K Ryder, CE Gillett. *J Pathol* 2002 196: 275-279
244. The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. EJ Sawyer, AM Hanby, AJ Rowan, CE Gillett, R Poulson, SR Lakhani, IO Ellis, P Ellis, IPM Tomlinson. *J Pathol* 2002 196: 437-444
245. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. RR Millis, R Springall, AHS Lee, K Ryder, ERC Rytina, IS Fentiman. *Br J Cancer* 2002 **86**: 396-401
246. BAG-1 expression in human breast cancer: Inter-relationship between BAG-1 RNA, protein, HSC70 expression and clinico-pathological data. PA Townsend, E Dublin, IR

Hart, R Kao, AM Hanby, RI Cutress, R Poulson, K Ryder, DM Barnes, G Packham. *J Pathol* 2002 197: 51-59

247. Investigations on a clinically and functionally unusual and novel germline *p53* mutation. J Rutherford, CE Chu, PM Duddy, RS Charlton, P Chumas, GR Taylor, X Lu, DM Barnes, RS Camplejohn. *Br J Cancer* 2002 **86**: 1592-1596
248. Paget disease of the nipple - A multifocal manifestation of higher-risk disease. AS Kothari, N Beechey-Newman, H Hamed, IS Fentiman, C D'Arrigo, AM Hanby, K Ryder. *Cancer* 2002 **95**: 1-7
249. Breast carcinoma in women age 25 years or less. AS Kothari, N Beechey-Newman, C D'Arrigo, AM Hanby, K Ryder, H Hamed, IS Fentiman. *Cancer* 2002 **94**: 606-614.
250. Re. The significance of intra-mammary nodes in primary breast cancer. N Beechey-Newman, C D'Arrigo. *Eur J Surg Oncol* 2001; **27**: 707-708. *Eur J Surg Oncol.* 2002; **28**(5): 565.
251. The PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues. Barrett, A., Madsen, B., Copier, J., Lu, P.-J., Cooper, L., Scibetta, A., Burchell. J. Taylor-Papadimitriou, J. (2002) *Int. J. Cancer* 101: 581-586
252. The role of E-cadherin in low-grade ductal breast tumourigenesis. R Roylance, S Droufakou, P Gorman, C Gillett, I R Hart, A Hanby, I Tomlinson. *J Pathol* 2003 **200**: 53-58
253. Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer. G Zhu, L Reynolds, T Crnogorac-Jurcevic, CE Gillett, EA Dublin, JF Marshall, D Barnes, C D'Arrigo, PO Van Trappen, NR Lemoine, IR Hart. *Oncogene* 2003 **22**: 3742-3748
254. MSI-Low, a real phenomenon which varies in frequency among cancer types. SER Halford, EJ Sawyer, MB Lambros, P Gorman, ND Macdonald, IC Talbot, WD Foulkes, CE Gillett, DM Barnes, LA Akslen, K Lee, IJ Jacobs, AM Hanby, TS Ganesan, HB Salvesen, WF Bodmer, IPM Tomlinson, RR Roylance. *J Pathol* 2003 **201**: 389-394
255. β -catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast. EJ Sawyer, AM Hanby, R Poulson, R Jeffery, CE Gillett, IO Ellis, P Ellis, IPM Tomlinson. *J Pathol* 2003 **200**: 627-632
256. The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: A retrospective

study of 2660 patients. DM Barnes, RR Millis, CE Gillett, K Ryder K, D Skilton D, IS Fentiman, RD Rubens. *Endocrine Related Cancer* 2004 **11**: 83-94

257. Human murine mammary tumour virus- like agents are genetically distinct from endogenous retroviruses and are not detectable in breast cancer cell lines or biopsies. C Mant, C Gillett, C D'Arrigo, J Cason. *Virology* 2004 **318**: 393-404
258. Endothelin-2 is chemotactic for breast carcinoma cells and increased invasion - a role for endothelin-2 and its receptors in breast tumour metastasis. MJ Grimshaw, T Hagemann, A Ayhan, C Gillett, FR Balkwill . *Cancer Res* 2004 **64**: 2461-2468
259. Molecular cytogenetic identification of sub-groups of grade III invasive ductal breast carcinomas with different clinical outcomes. Jones C, Ford E, Gillett C, Ryder K, Merret S, Reis-Filho JS, Fulford LG, Hanby A, Lakhani SR. (2004) *Clin Cancer Research* **10**:5988-5997.
260. A comprehensive study of chromosome16q in invasive ductal and lobular breast carcinoma using array CGH. Roylance R, Gorman P, Papior T, Wan Y-L, Ives M, Watson JE, Collins C, Wortham N, Langford C, Fiegler H, Carter N, Gillett C, Sasieni P, Pinder S, Hanby A, Tomlinson I (2006). *Oncogene* **25**: 6544-6553
261. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Fulford LG, Easton DF, Sofronis A, Reis-Filho JS, Gillett CE, Lakhani SR, Hanby A. (2006). *Histopathology* **49**:22-34.
262. An alternative method of dissecting mastectomy specimens. D'Arrigo C, Hanby AM, Springall RJ, Gillett CE, Millis RR. (2006). *Histopathology* **48**:608.
263. Use of a BRCA1 peptide validates MS110 as a BRCA1 specific antibody in imunohistochemistry. Alamshah A, Springall R, Gillett CE, Solomon E and Morris JR (2008). *Histopathology* **53**: 117-120
264. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, Easton D, Lakhani SR (2007). *Breast Cancer Res.* Jan 11;9(1):R4
265. BRCA1 Pathway Dysfunction in Sporadic Basal-like Breast Cancer. Turner NC, Reis-Filho JS, Russell A, Springall R, Ryder K, Steele D, Gillett C, Schmitt FC, Tutt A, Ashworth A. (2007). *Oncogene* **26**:2126-32
266. Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas through use of genomic grade. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillett C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JGM, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C (2007). *J Clin Onc.* **25**: 1239-46.
267. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J,

- Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F (2008). *BMC Cancer* **8**: 339.
268. mRNA expression profiling of phyllodes tumours of the breast: identification of genes important in the development of borderline and malignant phyllodes tumours. Jones AM, Mitter R, Poulson R, Gillett C, Hanby AM, Tomlinson IP, Sawyer EJ; Phyllodes Tumour Consortium (2008). *J Pathol.* **216**: 408-17.
269. 'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials. Kilburn LS; TNT Trial Management Group (2008). *Clin Oncol (R Coll Radiol)* **20**: 35-9
270. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. Jones AM, Mitter R, Springall R, Graham T, Winter E, Gillett C, Hanby AM, Phyllodes Tumour Consortium, Tomlinson IP, Sawyer EJ (2008). *J Pathol* **214**: 533-544
271. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C. *BMC Genomics.* 2008 May 22;9:239
272. Prognosis of synchronous bilateral breast cancer. Irvine T, Allen DS, Gillett C, Hamed H, Fentiman IS (2009). *Br J Surg.* **96**: 376-80.
273. A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens. Iverson AA, Gillett C, Cane P, Santini CD, Vess TM, Kam-Morgan L, Wang A, Eisenberg M, Rowland CM, Hessling JJ, Broder SE, Sninsky JJ, Tutt A, Anderson S, Chang SY (2009). *J Mol Diagn.***11**: 117-30.
274. A metadata approach for clinical data management in translational genomics studies in breast cancer. Papatheodorou I, Crichton C, Morris L, Maccallum P; METABRIC Group, Davies J, Brenton JD, Caldas C. *BMC Med Genomics.* 2009 Nov 30;2:66.
275. The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. Kelleher MT, Fruhwirth G, Patel G, Ofo E, Festy F, Barber PR, Ameer-Beg SM, Vojnovic B, Gillett C, Coolen A, Kéri G, Ellis PA, Ng T. *Target Oncol.* 2009 Sep;4(3):235-52
276. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A. *Cancer Res.* 2010 Mar 1;70(5):2085-94.
277. Epitheliosis, infiltrating epitheliosis, and radial scar. Eusebi V, Millis RR. *Semin Diagn Pathol.* 2010 Feb;27(1):5-12.
278. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Loi S, Haibe-Kains B,

Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C (2010). Proc Natl Acad Sci U S A.;107(22):10208-13

279. Risk factors for regional nodal relapse in breast cancer patients with 1-3 positive axillary nodes Yates L, Kirby A, Crichton S, Gillett C, Cane P, Sawyer E (2011). . IJROBP (in press).
280. Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways. Vichapat V, Gillett C, Fentiman IS, Tutt A, Holmberg L, Lüchtenborg M. Eur J Cancer. 2011;47(13):1919-27.
281. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC. Breast Cancer Res Treat. 2011;129(2):607-16
282. Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Lüchtenborg M. Breast Cancer Res Treat. 2011;130(2):609-18.
283. Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Julien S, Ivetic A, Grigoriadis A, QiZe D, Burford B, Sproviero D, Picco G, Gillett C, Papp SL, Schaffer L, Tutt A, Taylor-Papadimitriou J, Pinder SE, Burchell JM. Cancer Res. 2011 15;71(24):7683-93.
284. DART: Denoising Algorithm based on Relevance network Topology improves molecular pathway activity inference. Yan Jiao, Katherine Lawler, Gargi S Patel, Arnie Purushotham, Annette F Jones, Anita Grigoriadis, Andrew Tutt, Tony Ng, Andrew E Teschendorff. BMC Bioinformatics 2011, 12:403
285. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S, Evans DG, Ross G, Eccles D, Tutt A, Rahman N; TNT Trial TMG; BCSC (UK). Br J Cancer. 2012 Mar 13;106(6):1234-8
286. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S; METABRIC Group; Co-chairs, Caldas C, Aparicio S. Nature. 2012 Apr 18.
287. Patterns of metastasis in women with metachronous contralateral breast cancer. Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Lüchtenborg M. Br J Cancer. 2012 Jul 10;107(2):221-3

288. Targeting the HOX/PBX dimer in breast cancer. Morgan R, Boxall A, Harrington KJ, Simpson GR, Gillett C, Michael A, Pandha HS. *Breast Cancer Res Treat.* 2012 Nov;136(2):389-98.
289. Classification of terahertz-pulsed imaging data from excised breast tissue. AJ. Fitzgerald, S Pinder, AD Purushotham, P O'Kelly, PC. Ashworth, and VP. Wallace. *J. Biomed. Opt.* 2012; 17; 016005.01-016005.10.
290. Ductal carcinoma in situ: current morphological and molecular subtypes. JP Brown and SE Pinder. *Diagnostic Histopathology.* 2012; 18;112-118.
291. The life history of 21 breast cancers. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW et al; Breast Cancer Working Group of the International Cancer Genome Consortium. *Cell.* 2012 May 25;149(5):994-1007
292. Mutational processes molding the genomes of 21 breast cancers. Nik-Zainal S, Alexandrov LB, Wedge DC, et al; Breast Cancer Working Group of the International Cancer Genome Consortium. *Cell.* 2012 May 25;149(5):979-93.
293. Pinder SE, Brown JP, Gillett C, Purdie CA, Speirs V, Thompson AM, Shaaban AM; on behalf of the Translational Subgroup of the NCI Breast Clinical Studies Group. The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. *J Clin Pathol.* 2013 Mar;66(3):169-77
294. Gazinska P, Grigoriadis A, Brown JP, Millis RR, Mera A, Gillett CE, Holmberg LH, Tutt AN, Pinder SE. Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. *Mod Pathol.* 2013 Jul;26(7):955-66
295. Youssef G, Gillett C, Agbaje O, Crompton T, Montano X. Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: A potential novel prognostic marker for breast cancer. *Mod Pathol* 2014 Mar;27(3):361-74
296. de Rinaldis E, Gazinska P, Mera A, Modrusan Z, Fedorowicz GM, Burford B, Gillett C, Marra P, Grigoriadis A, Dornan D, Holmberg L, Pinder S, Tutt A. Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. *BMC Genomics.* 2013 Sep 23;14(1):643
297. Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. *Breast Cancer Res.* 2013 Oct 31;15(5):R103
298. Wong PP, Yeoh CC, Ahmad AS, Chelala C, Gillett C, Speirs V, Jones JL, Hurst HC. Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer. *Oncogene.* 2014 Mar 24; [Epub ahead of print]
299. Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, Fletcher O, Pinder S, Hanby A, Kohut K, Gorman P, Caneppele M, Peto J, Dos Santos Silva I,

Johnson N, Swann R, Dwek M, Perkins KA, Gillett C et al. Genetic predisposition to in situ and invasive lobular carcinoma of the breast. *PLoS Genet*. 2014 Apr 17 [Epub ahead of print]

300. Purushotham A, Shamil E, Cariati M, Agbaje O, Muhidin A, Gillett C, Mera A, Sivanadiyan K, Harries M, Sullivan R, Pinder SE, Garmo H, Holmberg L. Age at diagnosis and distant metastasis in breast cancer – A surprising inverse relationship. *Eur J Cancer*. 2014 Jul;50(10):1697-705
301. Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR, Haider S, Brouillette K, Saha A, Vallath S, Bowen R, Chelala C, Eccles D, Tapper WJ, Thompson AM, Quinlan P, Jordan L, Gillett C, Brentnall A, Violette S, Weinreb PH, Kendrew J, Barry ST, Hart IR, Jones JL, Marshall JF. Therapeutic targeting of integrin $\alpha\beta 6$ in breast cancer. *J Natl Cancer Inst*. 2014 Jun 28;106(8).
302. Veeriah S, Leboucher P, de Naurois J, Jethwa N, Nye E, Bunting T, Stone R, Stamp G, Calleja V, Jeffrey SS, Parker PJ, Larijani B. High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer. *Cancer Res*. 2014 Jun 26.
303. Harries M, Taylor A, Holmberg L, Agbaje O, Garmo H, Kabilan S, Purushotham A. Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. *Cancer Epidemiol*. 2014 Aug;38(4):427-34.
304. Weitsman G, Lawler K, Kelleher MT, Barrett JE, Barber PR, Shamil E, Festy F, Patel G, Fruhwirth GO, Huang L, Tullis ID, Woodman N, Ofo E, Ameer-Beg SM, Irshad S, Condeelis J, Gillett CE, Ellis PA, Vojnovic B, Coolen AC, Ng T. Imaging tumour heterogeneity of the consequences of a PKC α -substrate interaction in breast cancer patients. *Biochem Soc Trans*. 2014 Dec 1;42(6):1498-505.
305. Youssef G, Gillett C, Agbaje O, Crompton T, Montano X Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: a potential novel prognostic marker for breast cancer. *Mod Pathol*. 2014 Mar;27(3):361-74.
306. Irshad S, Gillett C, Pinder SE, A'hern RP, Dowsett M, Ellis IO, Bartlett JM, Bliss JM, Hanby A, Johnston S, Barrett-Lee P, Ellis P, Tutt A. Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer. *Breast Cancer Res Treat*. 2014 Apr;144(2):331-41
307. Weitsman G, Lawler K, Kelleher MT, Barrett JE, Barber PR, Shamil E, Festy F, Patel G, Fruhwirth GO, Huang L, Tullis ID, Woodman N, Ofo E, Ameer-Beg SM, Irshad S, Condeelis J, Gillett CE, Ellis PA, Vojnovic B, Coolen AC, Ng T. Imaging tumour heterogeneity of the consequences of a PKC α -substrate interaction in breast cancer patients. *Biochem Soc Trans*. 2014 Dec;42(6):1498-505. doi: 10.1042/BST20140165. Review.
308. Joshi S, Watkins J, Gazinska P, Brown JP, Gillett CE, Grigoriadis A, Pinder SE. Digital imaging in the immunohistochemical evaluation of the proliferation markers

Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value. *BMC Cancer*. 2015 Jul 25;15:546. doi: 10.1186/s12885-015-1531-3.

309. Watkins J, Weekes D, Shah V, Gazinska P, Joshi S, Sidhu B, Gillett C, Pinder S, Vanoli F, Jasin M, Mayrhofer M, Isaksson A, Cheang MC, Mirza H, Frankum J, Lord CJ, Ashworth A, Vinayak S, Ford JM, Telli ML, Grigoriadis A, Tutt AN. Genomic Complexity Profiling Reveals That *HORMAD1* Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. *Cancer Discov*. 2015 May;5(5):488-505. doi: 10.1158/2159-8290.CD-14-1092. Epub 2015 Mar 13.
310. Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah S, Lingjærde OC, Yuan Y, Ng CK, Dunning MJ, Dicks E, Provenzano E, Sammut S, McKinney S, Ellis IO, Pinder S, Purushotham A, Murphy LC, Kristensen VN; METABRIC Group, Brenton JD, Pharoah PD, Børresen-Dale AL, Aparicio S, Caldas C. A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. *Mol Oncol*. 2015 Jan;9(1):115-27. doi: 10.1016/j.molonc.2014.07.019. Epub 2014 Aug 8
311. Carmona G, Perera U, Gillett C, Naba A, Law AL, Sharma VP, Wang J, Wyckoff J, Balsamo M, Mosis F, De Piano M, Monypenny J, Woodman N, McConnell RE, Mouneimne G, Van Hemelrijck M, Cao Y, Condeelis J, Hynes RO, Gertler FB, Krause M. Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE. *Oncogene*. 2016 Mar 21. doi: 10.1038/onc.2016.47.
312. Melvin JC, Wulaningsih W, Hana Z, Purushotham AD, Pinder SE, Fentiman I, Gillett C, Mera A, Holmberg L, Van Hemelrijck M. Family history of breast cancer and its association with disease severity and mortality. *Cancer Med*. 2016 Jan 22. doi: 10.1002/cam4.648. [Epub ahead of print]
313. Melvin JC, Purushotham AD, Garmo H, Pinder SE, Fentiman IS, Gillett C, Mera A, Lütchtnborg M, Holmberg L, Van Hemelrijck M. Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time. *Br J Cancer*. 2016 Jan 12;114(1):88-95. doi: 10.1038/bjc.2015.314. Epub 2015 Dec 10.
314. Noor AM, Holmberg L, Gillett C, Grigoriadis A. Big Data: the challenge for small research groups in the era of cancer genomics. *Br J Cancer*. 2015 Nov 17;113(10):1405-12. doi: 10.1038/bjc.2015.341. Epub 2015 Oct 22. Review.
315. Woodman N, Pinder SE, Tajadura V, Le Bourhis X, Gillett C, Delannoy P, Burchell JM, Julien S. Two E-selectin ligands, BST-2 and LGALS3BP, predict metastasis and poor survival of ER-negative breast cancer. *Int J Oncol*. 2016 Jul;49(1):265-75
316. Weitsman G, Barber PR, Nguyen LK, Lawler K, Patel G, Woodman N, Kelleher MT, Pinder SE, Rowley M, Ellis PA, Purushotham AD, Coolen AC, Kholodenko BN, Vojnovic B, Gillett C, Ng T. HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. *Oncotarget*. 2016 Aug 9;7(32):51012-51026.

317. Gracio F, Burford B, Gazinska P, Mera A, Mohd Noor A, Marra P, Gillett C, Grigoriadis A, Pinder S, Tutt A, de Rinaldis E. Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival. *Sci Rep.* 2017 Jan 6;7:40177.
318. Irshad S, Flores-Borja F, Lawler K, Monypenny J, Evans R, Male V, Gordon P, Cheung A, Gazinska P, Noor F, Wong F, Grigoriadis A, Fruhwirth GO, Barber PR, Woodman N, Patel D, Rodriguez-Justo M, Owen J, Martin SG, Pinder SE, Gillett CE, Poland SP, Ameer-Beg S, McCaughan F, Carlin LM, Hasan U, Withers DR, Lane P, Vojnovic B, Quezada SA, Ellis P, Tutt AN, Ng T. RORYt⁺ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers. *Cancer Res.* 2017 Mar 1;77(5):1083-1096.
319. Shah V, Nowinski S, Levi D, Shinomiya I, Kebaier Ep Chaabouni N, Gillett C, Grigoriadis A, Graham TA, Roylance R, Simpson MA, Pinder SE, Sawyer EJ. PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression. *Breast Cancer Res.* 2017 Jan 17;19(1):7.
320. Lawler K, Papouli E, Naceur-Lombardelli C, Mera A, Ougham K, Tutt A, Kimbung S, Hedenfalk I, Zhan J, Zhang H, Buus R, Dowsett M, Ng T, Pinder SE, Parker P, Holmberg L, Gillett CE, Grigoriadis A, Purushotham A. Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. *Breast Cancer Res.* 2017 Oct 13;19(1):113.
321. Garcia-Dios DA, Levi D, Shah V, Gillett C, Simpson MA, Hanby A, Tomlinson I, Sawyer EJ. MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours. *Br J Cancer.* 2018 Jan;118(2):277-284.
322. Grigoriadis A, Gazinska P, Pai T, Irhsad S, Wu Y, Millis R, Naidoo K, Owen J, Gillett CE, Tutt A, Coolen AC, Pinder SE. Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers. *J Pathol Clin Res.* 2018 Jan 8;4(1):39-54.
323. Cheung A, Opzoomer JW, Ilieva KM, Gazinska P, Hoffmann RM, Mirza H, Marlow R, Francesch-Domenech E, Fittall MW, Dominguez Rodriguez D, Clifford A, Badder L, Patel N, Mele S, Pellizzari G, Bax HJ, Crescioli S, Petranyi G, Larcombe-Young D, Josephs DH, Canevari S, Figini M, Pinder SE, Nestle FO, Gillett C, Spicer J, Grigoriadis A, Tutt A, Karagiannis SN. Anti-Folate Receptor alpha-directed Antibody Therapies Restrict the Growth of Triple Negative Breast Cancer. *Clin Cancer Res.* 2018 Aug 1.